Cepheid

Cepheid’s GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, Tuberculosis and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. We call this the PCRplus advantage.

Approach to Healthcare

To know Cepheid is to know our spirit of innovation. It is what compelled us to reinvent the industry’s approach to molecular diagnostic testing. Our founders envisioned A Better Way for healthcare professionals to access the accuracy of real-time PCR in a faster, more flexible, scalable, and user-friendly format — one that could extend beyond the laboratory. Our commitment to improve patient care with faster, more accurate answers is at the heart of everything we do. We call it the PCRplus advantage.

Impact of Product/Services on Healthcare

Cepheid’s products significantly improve healthcare by delivering rapid, accurate molecular diagnostics that support early detection, faster clinical decisions, and better patient outcomes. Their GeneXpert® systems and broad Xpert® test portfolio streamline complex testing, reduce turnaround times, and enhance infection control through reliable identification of critical pathogens. Widely adopted across NHS Trusts, Cepheid enables scalable, on‑demand testing that strengthens antimicrobial stewardship and improves patient flow in acute settings. By integrating into clinical pathways and supporting timely interventions, Cepheid’s solutions help minimise hospital outbreaks, optimise therapy, and elevate standards of care across both central laboratories and point‑of‑care environments.

Innovation

When Cepheid introduced our first automated molecular diagnostics system more than two decades ago, we set a standard for innovation that continues to guide us. And now, even with the largest installed base of any molecular platform, Cepheid is constantly innovating and evolving our capabilities. Our technology has been heralded as game-changing by healthcare leaders world-wide. We envision a better way for clinical institutions of any size, from small medical clinics to high-volume reference laboratories and major hospitals, to access the power of molecular diagnostics. Our GeneXpert® System delivers fast, scalable, and accurate diagnostic results while our expanding Xpert® test menu spans multiple clinical applications such as healthcare-associated infections, sexual health, critical infectious disease, virology, and oncology

Future Direction

Cepheid’s future plans focus on expanding rapid, on‑demand molecular testing through next‑generation respiratory and GI panels, alongside continued evolution of the GeneXpert® platform to enhance speed, scalability, and usability. Innovation efforts include strengthened AI integration across R&D and commercial functions, and programs like the Acceleration Lab that empower associates to drive impactful ideas. Cepheid will also advance AMR‑focused initiatives, such as early CPE detection, and deepen collaboration across Danaher Diagnostics to deliver integrated, data‑driven solutions. Together, these initiatives aim to improve diagnostic accuracy, streamline workflows, and strengthen global health outcomes.